Company intelligence / Profile preview

Prognica Labs

Dubai, United Arab Emiratesprognica.com ↗

Ownership: Private
Employees: ~10
Development stage: Commercial

Overview

Prognica Labs has developed an AI-powered diagnostic suite that automates the analysis of mammograms, enhances ultrasound imaging interpretation, and analyzes histopathology slides to improve accuracy in detecting and classifying breast cancers. The company’s tools are designed to increase accessibility and affordability of early breast cancer screening. No clinical trial data reported; products are deployed as decision-support tools.

Therapeutic areas: Oncology
Modalities: Device (AI-powered software for image analysis)Non-pharmacological therapy (diagnostic platform)Artificial intelligence-based diagnostics
Industry: Digital Health Medical Devices

Drug pipeline

3 assets

Syrelix

Commercial

Indications: Cancer

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Prognica Labs.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Prognica Labs.

Explore the full profile